CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akashi Therapeutics, Inc., a clinical stage biopharmaceutical company developing treatments for Duchenne muscular dystrophy, today announced the presentation of preliminary positive clinical data for its most advanced drug candidate, HT-100 (delayed-release halofuginone), an orally available, small molecule developed to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with Duchenne muscular dystrophy (DMD). Preliminary clinical data for HT-100 on the first DMD patient cohorts suggests promising signs of biological activity and a favorable safety profile to date in this ongoing phase 1b/2a multi-center clinical program to evaluate the safety and tolerability of increasing doses of HT-100 and assess trends in a range of exploratory biomarkers and efficacy endpoints. The preliminary Phase 1b/2a data was presented at the New Directions in Biology and Disease of Skeletal Muscle 6th Biennial Conference held in Chicago June 29 through July 2, 2014.
Help employers find you! Check out all the jobs and post your resume.
